GLP-1 receptor agonists semaglutide and tirzepatide are associated with reduced risks of dementia, stroke, and mortality in adults with type 2 diabetes and obesity, new data show.

With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent ...

A new study suggests that drugs like Ozempic and Mounjaro may reduce dementia risk. Researchers at the University of Galway ...

An investigation has found at least 74 complaints have been made to hospital managers across England in the past 12 months.

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.